An Open Label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer

Trial Profile

An Open Label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms LISAH
  • Sponsors Roche
  • Most Recent Events

    • 03 Mar 2014 According to the the ClinicalTrials.gov record, status changed from suspended to discontinued.
    • 16 Nov 2013 Status changed from completed to suspended as reported by European Clinical Trials Database.
    • 16 Oct 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top